- Home
- RIGL vs LNKB Comparison
RIGL vs LNKB Comparison
Compare RIGL & LNKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- LNKB
- Stock Information
- Founded
- RIGL 1996
- LNKB 2018
- Country
- RIGL United States
- LNKB United States
- Employees
- RIGL N/A
- LNKB N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- LNKB
- Sector
- RIGL Health Care
- LNKB
- Exchange
- RIGL Nasdaq
- LNKB Nasdaq
- Market Cap
- RIGL 247.1M
- LNKB 263.0M
- IPO Year
- RIGL 2000
- LNKB N/A
- Fundamental
- Price
- RIGL $22.07
- LNKB $7.43
- Analyst Decision
- RIGL Buy
- LNKB Hold
- Analyst Count
- RIGL 4
- LNKB 1
- Target Price
- RIGL $31.13
- LNKB $7.50
- AVG Volume (30 Days)
- RIGL 151.9K
- LNKB 40.3K
- Earning Date
- RIGL 11-07-2024
- LNKB 10-28-2024
- Dividend Yield
- RIGL N/A
- LNKB 4.06%
- EPS Growth
- RIGL N/A
- LNKB 52.78
- EPS
- RIGL 0.22
- LNKB 0.17
- Revenue
- RIGL $156,374,000.00
- LNKB $86,138,000.00
- Revenue This Year
- RIGL $38.26
- LNKB N/A
- Revenue Next Year
- RIGL $24.21
- LNKB $3.66
- P/E Ratio
- RIGL $99.67
- LNKB $43.98
- Revenue Growth
- RIGL 19.95
- LNKB 151.50
- 52 Week Low
- RIGL $7.48
- LNKB $5.86
- 52 Week High
- RIGL $22.85
- LNKB $8.29
- Technical
- Relative Strength Index (RSI)
- RIGL 83.76
- LNKB 65.43
- Support Level
- RIGL $13.91
- LNKB $6.73
- Resistance Level
- RIGL $14.70
- LNKB $7.73
- Average True Range (ATR)
- RIGL 1.04
- LNKB 0.27
- MACD
- RIGL 0.50
- LNKB 0.09
- Stochastic Oscillator
- RIGL 91.59
- LNKB 80.53
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans.